YoungSolvers

Next Generation of Drug Designers

Young scientists are the future. Their success is determined by encouragement of the scientific community, the accessibility to knowledge, and the right tools to apply it.
'YoungSolvers' aims to support individual master thesis projects in Europe with a free-of-charge two month license for our software. With this we encourage independent creative research conveniently from home.

Profit from BioSolveIT's
drug discovery package

SeeSAR 3D desktop molecular modeling platform

SeeSAR

SeeSAR is a user-friendly drug design platform. Start from a small fragment-binder and evolve it to full-fledged drug candidate, screen libraries to predict active binders, or work interactively with a known binder to increase it's affinity. SeeSAR offers all the tools to support drug discovery beginners and veterans alike.
For more information read the SeeSAR PDF.
infiniSee screening platform

infiniSee

infiniSee is a navigation platform to find similar molecules in Chemical Spaces. Start with an active query molecule and search for distant neighbours for your target. The twist behind it: all molecules are accessible and can be purchased or easily synthesized by yourself.
For more information read the infiniSee PDF.
Knime icon big

Knime Workflows

KNIME is a modular, extendable data exploration platform to visually create workflows. The provided BioSolveIT workflows (FragXplorer, REALizer, BioSphere, MedChemWizard) themselves are easily adjustable to your project and can be a great help to set up your project.

Profit from BioSolveIT's
drug discovery package

Once you got access to our software, you can benefit from several educational BioSolveIT services. We offer virtual workshops on our software and applications, as well as a variety of tutorials and short-educational videos.

Help

FAQ

To apply for YoungSolvers you need to provide:
  • Official confirmation of your status as a Masters student (e.g. student ID, enrollment at university)
  • Filled-out form signed by your supervisor
Send both in a single PDF to youngsolvers@biosolveit.de.

Please note: As of today, BioSolveIT is happy to support Master students at European Universities only. Depending on acceptance, potential legal constraints, and other factors, the concept may be extended to other areas in the world in the future.
No. Our YoungSolvers licenses come with no strings attached. We explicitly do not claim any rights on intellectual proprietary resulting from the master thesis. Also, there are no license fees. For two months you will get free access to the applications and workflows. We want to provide our state-of-the-art software to young scientist to encourage them in their research without any monetary gain.
Our Scientific Challenge Winners have contributed many successful stories with our software. You may find some ideas to implement in your project there.
We offer interactive workshops for YoungSolvers to support them with their project. The workshops will be recorded and can be accessed afterwards on youtube. If the workshop is of interest to you, you can participate even as a non-member of YoungSolvers.
  • Introduction to SeeSAR and infiniSee (Recording)
  • From Fragment to Drug Candidate with SeeSAR (Recording)
  • Stumbling Blocks in Drug Design - Applied Medicinal Chemistry (Recording)
Once you received your approval confirmation, you need to confirm your license request one week (7 days) ahead of the beginning of the license. With this we offer a flexible starting date of the license in case of delays.
Simply send an informal request seven days ahead to youngsolvers@biosolveit.de.

Case Example 1
Fragment Evolution

Start with a small fragment binder (e.g. PDB-ID: 3OOG) with the working hypothesis to design more potent derivatives. Use SeeSAR to describe and analyze the binding site, discover unnoccupied cavities, and prepare high-quality visuals. Important structural contributions of the ligand to it's affinity can be characterized with the implemented HYDE affinity estimation to generate ideas where optimizations can be made. Add functional groups or whole substructures to further increase the potency of your ligand. Once you are done, you can check if your drug candidates can be easily synthesized in the virtual KnowledgeSpace with infiniSee.

Case Example 2
Scaffold Hopping

You start with a molecule that contains an unwanted motif (e.g. toxic, unfavorable physico-chemical properties, patent-protected). With SeeSAR you can design new molecules or replace whole scaffolds with the ReCore functionality of the Inspirator Mode. The designed molecules can further be characterized for their physico-chemical properties (log P, solubility, lipophilic ligand efficiency, ...) as well as their toxicologic profile (hERG IC50, P-gp, ability to penetrate the blood brain barrier, ...). Additionally, you can perform a fuzzy similarity search with infiniSee to find novel, accessible models in our Chemical Spaces and assess those for their safety profiles.
category
Events
BioSolveIT at 34th GP2A 2026 Conference on Medicinal Chemistry in Gothenburg
December 17, 2025 15:19 CET
BioSolveIT is honored and excited to participate in the 34th GP2A 2026 Conference on Medicinal Chemistry in Gothenburg. From August 26 to 28, 2026, the Group for the Promotion of Pharmaceutical Chemistry in Academia (GP2A), a member-led network of academic medicinal chemists working at universities and research institutes in Europe,...
Read on
category
Webinars
Why AI Can't Produce Novelty: How to Build Workflows for IP Generation
Wed, 28 Jan 2026, 16:00 CET (Berlin)
AI and machine learning can achieve a lot in drug discovery, but a fundamental limitation often shows up when you push beyond known chemistry: the generation of truly novel, viable scaffolds. Most workflows learn from existing data and can reliably suggest candidates that improve properties within familiar chemical space. But...
Read on
BioSolveIT wrapped 2025
December 15, 2025 06:18 CET
Our Year in Drug Discovery In 2025, we focused on bridging the gap between computational prediction and compound tangibility. Along the way we refined and evolved our platforms to ensure that drug discovery is not only faster, but also more accessible and reliable for researchers everywhere. This year saw the...
Read on